Different efficacy of various blocking reagents to eliminate interferences by human antimouse antibodies with a two-site immunoassay

Clinical Biochemistry

Volumn 29, Issue 2, 1996, Pages 145-148

  Reinsberg, Jochen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

CA 125; human antimouse antibodies; immunoassay; interference

Indexed keywords

ANTIBODY; BLOCKING AGENT; CA 125 ANTIGEN; HUMAN MOUSE ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY OC 125; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; SERUM;

EID: 0029913059     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-9120(95)02044-6     Document Type: Article

References (16)

1. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassay. Clin Chem 1988; 34: 27-33.
2. 2 fragments of the OC125 antibody. Clin Chem 1993; 39: 891-6.
3. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA-125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993; 39: 2509-13.
4. Reinsberg J, Gast B. Human anti-idiotypic antibodies against OC125 strongly interfere with one-step assays of CA 125 employing OC125 and M11 antibodies. Clin Chem 1994; 40: 951-2.
5. Reinsberg J, Richter H. Determination of the Cancer Antigen 125 with a second generation assay - Interferences by human anti-OC125 antibodies. Clin Lab 1995; 41: 345-50.
6. Bienhaus G, Mössner E, Lenz H. Anti-interference for immunoassays with monoclonal antibodies. In: Klapdor R, Ed. Recent results in tumor diagnosis and therapy. Pp. 469-71. Müchen: Zuckschwerdt Verlag, 1990.
7. Kricka LJ, Schmerfeld-Pruss D, Senior M, Goodman DBP, Kaladas P. Interference by human anti-mouse antibody in two-site immunoassays. Clin Chem 1990; 36: 892-4.
8. Boerman OC, Segers MFG, Poels LG, Kenemans P, Thoma CMG. Heterophilic antibodies in human sera causing falsely increased results in the CA-125 immunofluorometric assay. Clin Chem 1990; 36: 888-91.
9. Reinsberg J. Interference by human antibodies with tumormarker assays. Hybridoma 1995; 14: 205-8.
10. Boscato LM, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem 1986; 32: 1491-5.
11. Thompson RJ, Jackson AP, Langlois N. Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects - Incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme. Clin Chem 1986; 32: 476-81.
12. Howanitz PJ, Howanitz JH, Lamberson HV, Ennis KM. Incidence and mechanism of spurious increases in serum thyrotropin. Clin Chem 1982; 28: 427-31.
13. Zeng ZC, Tang ZY, Liu KD, Lu JZ, Cai XJ, Xie H. Human anti-(murine IgG) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-labeled Hepatam-1 mAb. Preliminary results and discussion. Cancer Immunol Immunother 1994; 39: 332-6.
14. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45: 5910-3.
15. Reynolds JC, Del Vecchio S, Sakahara H, et al. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Nuc Med Biol 1989; 16: 121-5.
16. Schulz G, Buchler M, Muhrer KH. Immunotherapy of pancreatic cancer with monoclonal anti BW 494. Int J Cancer 1988; Suppl 2: 89-94.